Efficacy of Amphotericin B on COVID-19: A Case Report Study
-
Published:2022-02-26
Issue:1
Volume:8
Page:
-
ISSN:2413-0516
-
Container-title:Journal of Contemporary Medical Sciences
-
language:
-
Short-container-title:J. Contemp. Med. Sci.
Author:
Mehrpisheh Shahrokh,Farhadi Roya,Ghaffari Saravi Vajihe,Memarian Azadeh,Nikkhah Farahnaz
Abstract
The role of amphotericin B (AmB) as an antiviral drug against some enveloped viruses has been studied in previous researches. Coronavirus is an envelope, non-segmented and positive-sense RNA virus which may be targeted by AmB. Our case was a 34-day-old female child with a 4-days history of low consciousness and dry cough, which gradually became productive. The infant was cyanotic at the admission time that transferred to the Neonatal Intensive Care Unit (NICU). After discharge, we were informed that result of PCR (polymerase chain reaction) test was positive which has been first reported as a false negative result. So the results drove our attention to that amphotericin B may cause a dramatic response to the coronavirus. Because of the crucial role of the immune system in viral clearance, the AmB as an immune response and pro-inflammatory stimulator may pave the way for preventing invasion in viral infections such as COVID-19.
Publisher
Naba'a Al-Hayat Foundation for Medical Sciences and Health Care
Subject
Rehabilitation,Physical Therapy, Sports Therapy and Rehabilitation,General Medicine